Free Trial

Enfusion (ENFN) Stock Forecast & Price Target

Enfusion logo
$9.05
+0.14 (+1.57%)
(As of 11/1/2024 ET)

Enfusion - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
2
Buy
1

Based on 6 Wall Street analysts who have issued ratings for Enfusion in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 6 analysts, 3 have given a sell rating, 2 have given a hold rating, and 1 has given a buy rating for ENFN.

Consensus Price Target

$9.33
3.13% Upside
According to the 6 analysts' twelve-month price targets for Enfusion, the average price target is $9.33. The highest price target for ENFN is $11.00, while the lowest price target for ENFN is $8.00. The average price target represents a forecasted upside of 3.13% from the current price of $9.05.
Get the Latest News and Ratings for ENFN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Enfusion and its competitors.

Sign Up

ENFN Analyst Ratings Over Time

TypeCurrent Forecast
11/3/23 to 11/2/24
1 Month Ago
10/4/23 to 10/3/24
3 Months Ago
8/5/23 to 8/4/24
1 Year Ago
11/3/22 to 11/3/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$9.33$9.33$9.33$11.00
Forecasted Upside3.13% Upside4.99% Upside3.13% Upside27.83% Upside
Consensus Rating
Reduce
Reduce
Reduce
Hold

ENFN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ENFN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Enfusion Stock vs. The Competition

TypeEnfusionComputer and Technology CompaniesS&P 500
Consensus Rating Score
1.67
2.68
2.50
Consensus RatingReduceModerate BuyHold
Predicted Upside3.13% Upside326.00% Upside10.57% Upside
News Sentiment Rating
Neutral News

See Recent ENFN News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/10/2024Morgan Stanley
3 of 5 stars
 Initiated CoverageOverweight$11.00+21.95%
3/13/2024Bank of America
4 of 5 stars
 Boost TargetUnderperform ➝ Underperform$8.00 ➝ $9.00-1.85%
2/28/2024The Goldman Sachs Group
2 of 5 stars
 DowngradeNeutral ➝ Sell$9.00 ➝ $8.00-14.26%
1/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight$11.00 ➝ $9.00+5.88%
12/20/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$9.00 ➝ $10.00+0.40%
11/7/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$9.00+8.56%
11/16/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$14.00+4.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:28 PM ET.


ENFN Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Enfusion is $9.33, with a high forecast of $11.00 and a low forecast of $8.00.

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ENFN shares.

According to analysts, Enfusion's stock has a predicted upside of 3.13% based on their 12-month stock forecasts.

Analysts like Enfusion less than other "computer and technology" companies. The consensus rating for Enfusion is Reduce while the average consensus rating for "computer and technology" companies is Moderate Buy. Learn more on how ENFN compares to other companies.


This page (NYSE:ENFN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners